Biotec Pharmacon: Results for Q4 2017
(Tromsø, 01 February 2018) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 17.7 million (18.2) in the fourth quarter of 2017, and a negative EBITDA of NOK 7.2 million (-8.1). Sales for 2017 amounted to NOK 66.7 million (71.2) and the EBITDA was negative NOK 22.9 million (-19.0). The Company experienced sales growth within both ArcticZymes as well as within the wound care product Woulgan®.The annual sales within ArcticZymes grew from NOK 29 million in 2016 to NOK 32 million in 2017 despite one of its main customers spending part of 2016 restructuring their business and